Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors

BACKGROUND: Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) readministration to lung cancer patients is common owing to the few options available. Impact of clinical factors on prognosis of EGFR-mutant non-small cell lung cancer (NSCLC) patients receiving EGFR-TKI readministr...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yu-Mu, Lai, Chien-Hao, Rau, Kun-Ming, Huang, Cheng-Hua, Chang, Huang-Chih, Chao, Tung-Ying, Tseng, Chia-Cheng, Fang, Wen-Feng, Chung, Yu-Hsiu, Wang, Yi-Hsi, Su, Mao-Chang, Huang, Kuo-Tung, Liu, Shih-Feng, Chen, Hung-Chen, Chang, Ya-Chun, Chang, Yu-Ping, Wang, Chin-Chou, Lin, Meng-Chih
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5100346/
https://www.ncbi.nlm.nih.gov/pubmed/27821111
http://dx.doi.org/10.1186/s12885-016-2917-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5100346/
https://www.ncbi.nlm.nih.gov/pubmed/27821111
http://dx.doi.org/10.1186/s12885-016-2917-6

Ejemplares similares